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Introduction: To determine long-term outcome and risk factors for 
recurrence after thymectomy.
Methods: Patients who underwent thymectomy (n = 262) for a thy-
mic tumor (1986–2010) were identified from a prospective database. 
Patients were classified according to World Helath Organization (WHO) 
histologic classification, Masaoka staging system, and completeness 
of resection. Risk factors for recurrence: WHO histology, tumor size, 
Masaoka stage and completeness of resection were analyzed.
Results: Of 262 patients, 51% were female, median age was 55 
years, and 39% had myasthenia gravis. Median follow-up was 7.5 
years, median tumor size was 5.4 cm, and Masaoka stage distribution 
was: I (25%), II (47%), III (17%), IV (4%), and (7%) not classi-
fied. Of 200 patients classified under the WHO system, there were 
(7%) type A, (22%) type AB, and (71%) type B; 83% had complete 
resection. One-hundred and sixty-nine patients received adjuvant 
radiotherapy, eight adjuvant chemoradiotherapy and 14 neoadjuvant 
chemoradiotherapy. Overall survival was 95% at 5 years, 91% at 10 
years and 91% at 15 years. Recurrence occurred in 12 patients and 
disease-related death in four patients. Five patients underwent re-
resection for recurrence with survival of 2–15 years. Only Masaoka 
stage and tumor size were associated with statistically significant risk 
of recurrence on multivariate analysis.
Conclusion: Resectable thymoma is associated with excellent prog-
nosis. Aggressive resection of recurrent disease yielded excellent 
long-term results. Higher Masaoka stage is associated with a greater 
chance of incomplete resection. Higher Masaoka stage and increas-
ing tumor size are independent factors associated with recurrence.
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(J Thorac Oncol. 2014;9: 1018–1022)
Epithelial tumors of the thymus gland are rare neoplasms that exhibit significant histologic heterogeneity. This has 
contributed to long-standing controversy and uncertainty 
regarding best predictors of outcome. More recently, however, 
multivariate analyses performed in several retrospective case 
series have demonstrated tumor Masaoka stage and complete-
ness of resection to be consistent independent prognostic 
factors.1–3
Although the World Helath Organization (WHO) his-
tologic classification4 has been increasingly adopted as the 
classification of choice, recent multivariate analyses have gen-
erally not shown it to be of independent prognostic value.2,3,5 
There is, however, consensus that many of these tumors are 
relatively indolent and are associated with excellent long-term 
survival of greater than 75% at 10 years, warranting aggres-
sive surgical 50 intervention.
This retrospective study of a large cohort of thymoma 
patients was carried out to further the understanding of the 
association between survival and WHO histology, tumor size, 
Masaoka stage, and completeness of resection.
MATERIALS AND METHODS
This study was approved by the Research Ethics Board 
of University Health Network (Toronto General Hospital 
[TGH] and Princess Margaret Hospital). All patients with thy-
mic tumors who underwent thymic resection at TGH between 
1986 and 2010 were reviewed in this retrospective cohort. Data 
were collected from a prospectively maintained database, and 
all electronic and archived paper charts were reviewed. All sur-
gical pathology assessments were performed at TGH. Staging 
was recorded according to the Masaoka staging system and 
extent of resection was defined as microscopically complete 
versus incomplete. In patients in whom resection was per-
formed in the very early years, thymoma capsule invasion 
anteriorly even in the absence of extension outside of capsule 
used to be reported as “margin positive”. However, after care-
ful review, the investigators (surgeons and pathologists) felt 
this to be inaccurate considering that this aspect of the thymic 
capsule lies immediately posterior to the sternum where there 
is no other anatomical tissue to form a classic “surgical mar-
gin”. Hence, it was felt that such cases should be considered 
as complete resections. This reporting method was adopted 
and is used consistently in all cases performed since that early 
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period. Although the indications for adjuvant radiotherapy 
have evolved over the period of this study, in general, in all 
incomplete resections and stage 2b or greater, radiotherapy 
has generally been recommended. Neoadjuvant therapy was 
recommended only sparingly on an individual basis mostly in 
the context of downsizing larger tumors in the hope of achiev-
ing an R0 resection. Histologically, the WHO classification 
was used in many cases (200 of 262). Cases reported early in 
this cohort were either reported according to Lattes Bernatz24 
or thymoma not otherwise specified or “benign thymoma,”19 
as older slides were no longer physically available for review 
(Table 1). Follow-up was performed every 6 months for the 
first 2 years and then yearly with computed tomography tho-
rax. Histological WHO type C (undifferentiated/poorly dif-
ferentiated thymic carcinoma cases (n = 19) are reviewed in 
this report for completeness of the experience. However, this 
subtype is largely considered a separate entity and therefore is 
not included in any statistical analysis.
Descriptive statistics were reported as medians with 
ranges for continuous variables and frequencies and propor-
tions for categorical variables. Recurrence-free survival was 
calculated using the Kaplan-Meier method. Recurrence-free 
survival was defined as the time from surgery date to first 
recurrence (when identified on computed tomography scan 
either on routine follow-up or when done for clinical indica-
tions), death from disease, or last follow-up. There were very 
few events to analyze overall survival. Differences between 
survival curves were analyzed by Log-rank test. Multivariate 
analyses were performed using Cox-proportional hazard 
regression models. Hazard ratios and 95% confidence inter-
vals were estimated from the multivariate model. Two-sided 
tests were applied. Results are considered significant if the 
p value is less than 0.05. An exhaustive search for potential 
cutoffs for tumor size was performed to determine the opti-
mal size with the maximum effect between the large tumor 
and small tumor subgroups. All the other analyses are per-
formed using SAS 9.2 (SAS Institute, Cary, NC).
RESULTS
Of 262 patients, 133 (51%) were female, median age 
was 55 years (range 16–86), and 39% had myasthenia gravis. 
Median follow-up was 7.5 years (maximum 25 years; mini-
mum 1 year) and median tumor size was 5.4 cm (maximum 
17.5 cm, mininimum 1 cm). The Masaoka stage distribution 
was: I, 65 (25%); II, 123 (47%); III, 45 (17%); and IV, 10 
(4%). The pathological diagnosis of “benign and otherwise not 
classified thymoma” was reported in 19 (7%) of patients early 
in the cohort. Of 200 patients with known WHO staging, the 
histologic distribution was: type A, 14 (7%); AB. 44 (22%); 
and B, 142 (71%). Forty-three were classified only accord-
ing to Lattes-Bernatz and Rosai systems all of which involved 
patients also early on in data collection before the WHO clas-
sification was adopted at TGH. Two-hundred patients (83%) 
had a complete resection (R0) and 43 (17%) had an incom-
plete resection (41 R1: microscopic-positive margins, two 
R2: grossly positive margins). One-hundred and sixty-nine 
patients received adjuvant radiotherapy, four received adju-
vant chemoradiotherapy, and 14 received neoadjuvant chemo-
radiotherapy. Table 2 describes characteristics and treatment 
TABLE 1.  All Thymic Tumors Resected (1986–2010; 262)
WHO  
histology Non-WHO classification Thymic Ca
200 43 19
Lattes-Bernatz
24
“Benign thymoma”
19
None included 
in statistical 
analysis
Aside from variation in the reporting of histology all variables (Masaoka 
stage, tumor size etc.) were available on all above 243 cases.
WHO, World Helath Organization.
TABLE 2.  Demographic and Treatment Data by Masaoka 
Stage
Characteristic
Masaoka Stage
I II III IV
Gender (M/F) 29/36 49/74 30/15 2/8
Age (median, years) 56 54 57 51
Completeness of resection (R0—Y/N) 64/1 108/15 25/20 3/7
Adjuvant radiotherapy (Y/N) 17a/48 111/12 36/9 5/5
Neoadjuvant chemoradiation (Y/N) 0/65 5/118 8/37 1/9
Adjuvant chemoradiation 0/65 1/122 1/44 2/8
aRadiotherapy was administered to many stage I patients as they were felt to be 
R1 resection at the anterior margin and so initially classified as stage II as described in 
methods.
TABLE 3.  Masaoka Stage Versus World Helath Organization (WHO) Histology
Masaoka Stage
WHO Histology
A AB B1 B2 B3 Total
I 6 10 8 17 6 47 (23.5%)
II 6 29 14 43 13 105 (52.5%)
III 2 4 6 14 12 38 (19.0%)
IV 0 1 2 3 4 10 (5.0%)
Total 14 (7.0%) 44 (22.0%) 30 (15.0%) 77 (38.5 %) 35 (17.5%) 200a
aThere were 24 patients who were classified using the Lattes-Bernatz histology criteria (Table 3) and 19 patients from the earliest portion of the series who were classified as “benign, 
not otherwise classified—thymoma”. The latter were classified as stage I.
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by Masaoka stage. Table 3 compares WHO histology with 
Masaoka Stage.
Overall survival was 95% at 5 years, 91% at 10 years, 
and 91% at 15 years. Recurrence occurred in 12 patients 
(follow-up range 1–15 years) only three of which were local 
mediastinal recurrences. Disease-related death occurred in 
four patients. Five patients underwent re-resection for recur-
rent disease, four of whom had pleural metastases and one had 
mediastinal disease with subsequent survival of two to 15+ 
years at last follow-up. Three patients with recurrent disease 
underwent more than one re-resection including a pneumo-
nectomy in one patient.
On univariate analysis, increased Masaoka stage 
and incomplete resection were associated with statisti-
cally increased risk of recurrence with p values of less than 
0.0001 and less than 0.0009 respectively. Larger tumor size 
and increased age were also statistically significantly asso-
ciated with increased recurrence as continuous predictors 
(p < 0.0002 and p < 0.04, respectively). Specifically, the opti-
mal cut point for size was 7.0 cm (when it was dichotomized; 
p = 0.03; association with recurrence; see Fig. 2). On mul-
tivariate analysis, however, only increased Masaoka stage | 
(Fig. 1A, B) and size (as a continuous predictor) were associ-
ated with increased recurrence (p < 0.0001; p < 0.03) (Tables 4 
and 5). Gender, WHO histology (Fig. 1C), and adjuvant radio-
therapy did not prove to be statistically significant factors in 
relation to recurrence.
DISCUSSION
Surgically resectable thymoma remains a relatively rare 
tumor with an excellent long-term prognosis. It is, however, 
these same characteristics that have made it difficult to study 
this disease and determine with greater certainty a clear set of 
prognostic factors. Data pertaining to thymoma have largely 
continued to depend on reports of case series. Although the 
WHO histologic classification system has gained increasing 
acceptance, its clinical value in shaping clinical course and 
treatment has been difficult to define.6 Several large studies 
have shown tumor stage and completeness of resection to be 
independent risk factors on multivariate analysis.5–7 Others 
have suggested that patients with smaller tumors (independent 
FIGURE 1.  Recurrence-free survival (RFS) by Masaoka stage 
and World Helath Organization (WHO) histology. A, RFS by 
Masaoka stage (n = 243). (B) RFS by grouped Masaoka stage 
(n = 243). (C) RFS by WHO histology (n = 200).
FIGURE 2.  Recurrence-free survival by tumor size  
(dichotomized at 7 cm; n = 262)
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of stage) may indeed have a better prognosis. Myasthenia gra-
vis was initially described to be related to better prognosis, but 
this has in fact proven not to be the case upon adjusting for 
stage.7,8 This initial observation likely reflected earlier disease 
detection in patients who presented with myasthenia gravis 
and thus earlier stage at diagnosis. Epidemiological factors 
such as age and gender have also not been found to be of prog-
nostic value.
In the present case series and in keeping with other 
studies,1–3 Masaoka stage was an independent prognostic fac-
tor on multivariate analysis. No recurrences were observed in 
patients with Masaoka stages I and II compared with stages III 
and IV. In addition, tumor size was also an independent prog-
nostic factor with statistical significance. Particularly, tumors 
larger than 7.0 cm were associated with an increased risk of 
recurrence. This finding may suggest a potential indication or 
benefit for neoadjuvant therapy for these larger tumors; how-
ever, this would need to be studied further. Although some 
case series found that WHO histology is a prognostic factor 
and that types B2 and B3 were associated with poorer prog-
nosis, Type B1 was found to behave similarly to types A and 
AB,9–11 WHO histology in our series was not an independent 
predictor for recurrence on both univariate and multivariate 
analyses.
Completeness of resection was statistically associated 
with recurrence on univariate analysis but was not significant 
on multivariate analysis. However, this series had an 83.0% 
R0 resection rate and few recurrences; thus, completeness of 
resection, as the only controllable factor, may have contrib-
uted to these results.12 The goal of obtaining clear margins 
warrants aggressive surgical approach.
Our protocol at UHN has generally been to give radia-
tion to patients with Masaoka stage II and higher regardless 
of completeness of resection and only three patients had local 
mediastinal recurrence, one of whom had received postop-
erative radiation. Adjuvant radiation treatment remains con-
troversial and recommendations vary especially in cases of 
complete resection. In cases of incomplete resection, recent 
studies have suggested a trend towards decreased recurrence 
with radiation.13–15 However, in light of several series showing 
completeness of resection as an independent prognostic fac-
tor and incidence of recurrence in Masaoka stage II patients 
being very low, mediastinal radiation to stage II patients who 
had a complete resection should be reconsidered. We have 
indeed been using adjuvant radiation more selectively in 
recent years.
Overall survival in surgical series of more than 100 
patients at 5 years was 83–100% (stage I), 60–100% (stage 
II), 46–88% (stage III), and 24–70% (stage IV).3,5,7,16–18 The 
results observed in this study lie within this range. However, 
the recurrence rates observed in our center experience are 
lower. The cohort being studied, follow-up range and meth-
ods, however, are not dissimilar indicating any identifiable 
bias. As with all these case series, the indolent nature of 
disease, its relative infrequency, and wide range of follow-
up years makes identifying recurrence an ongoing effort 
required prolonged follow-up. It is our institutional policy 
to follow patients for life wherever feasible. Surgical resec-
tion of recurrence has been advocated by several studies 
with survival of up to 72% at 10 years particularly in com-
pletely re-resected tumors with a second recurrence rate of 
only 25%.19,20 Again this is in support of aggressive surgical 
TABLE 4.   Multivariate Models Incorporating Masaoka Stage, but Excluding Completeness of Resection (n = 200)a
Factor
Initial Multivariate Model Final Multivariate Model
Adjusted Hazard Ratio  
(95% Confidence Intervals) p
Adjusted Hazard Ratio  
(95% Confidence Intervals) P
Age (per year) 0.94 (0.88–1.01) 0.11
Gender (F vs. M) 12.3 (1.12–134) 0.04
World Helath Organization (A/AB vs. B) 0.72 (0.07–7.48) 0.79
Stage (3/4 vs. 1/2) 13.5 (1.38–132) 0.03 13.66 (1.45–128) 0.02
Tumor size 1.29 (1.03–1.61) 0.03 1.20 (1.01–1.43) 0.04
aCompleteness of resection was highly correlated with Masaoka stage (p < 0.0001). As a result, both variables could not be put into the same multivariate model. Masaoka Stage 
was included and tumor size remained as a primary significant factor after backwards selection of multivariate Cox Proportional Hazard regression models.
TABLE 5.   Multivariate Models Incorporating Completeness of Resection, but Excluding Masaoka Stage (n = 200)a
Factor
Initial Multivariate Model Final Multivariate Model
Adjusted Hazard Ratio (95% CI) p Adjusted Hazard Ratio (95% CI) P
Age (per year) 0.91 (0.83–1.00) 0.05
Gender (F vs. M) 18.02 (1.25–260) 0.03
World Helath Organization (A/AB vs. B) 1.17 (0.10–14.1) 0.90
Completeness of Resection (R1/R2 vs. R0) 5.93 (0.66–53) 0.11
Tumor size 1.44 (1.09–1.90) 0.01 1.36 (1.13–1.63) 0.001
aCompleteness of resection was highly correlated with Masaoka stage (p < 0.0001). As a result, both variables could not be put into the same multivariate model. Completeness of 
resection was included and tumor size remained as a primary significant factor after backwards selection of multivariate Cox-proportional hazard regression models.
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management. In some series, similar survival was observed 
for stage I and stage III if resection was complete. More 
extensive resection including superior vena cava resections 
have become more common to achieve R0 margins.21 In this 
present cohort, one patient remains alive and well 2 years 
after the third of three resections, the last of which included 
a completion pneumonectomy.
Thymoma remains a relatively uncommon tumor and 
therefore case series have been an important source of under-
standing the clinical course of the disease and the response to 
treatment. In our experience of 262 surgically resected cases, 
adverse prognostic factors included: incomplete resection, 
larger sized tumors (> 7 cm), and higher Masaoka stage. The 
excellent long-term survival of patients demonstrated with 
surgical resection with thymoma is encouraging and our data 
support continued efforts to safely achieve complete surgical 
resection wherever possible to affect long-term cure. In the 
few cases that do recur in the long term (Stage III and IV), 
further study is required to determine whether neoadjuvant or 
adjuvant chemotherapy and/or radiotherapy will improve the 
outcome.
REFERENCES
 1. Verley JM, Hollmann KH. Thymoma. A comparative study of clini-
cal stages, histologic features, and survival in 200 cases. Cancer 
1985;55:1074–1086.
 2. Pan CC, Wu HP, Yang CF, Chen WY, Chiang H. The clinicopathological 
correlation of epithelial subtyping in thymoma: a study of 112 consecu-
tive cases. Hum Pathol 1994;25:893–899.
 3. Ströbel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in 
patients treated for thymomas and thymic squamous cell carcinomas: a 
retrospective analysis. J Clin Oncol 2004;22:1501–1509.
 4. Rosai J, Sobin L. Histological typing of tumours of the thymus. In: Rosai 
J, Sobin L, eds. World Health Organization, International Histological 
Classification of Tumours. Berlin: Springer; 1999:9–14.
 5. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis 
of factors predicting survival. Ann Thorac Surg 1995;60:908–13; discus-
sion 914. 
 6. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization 
histologic classification system reflects the oncologic behavior of thy-
moma: a clinical study of 273 patients. Cancer 2002;94:624–632.
 7. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-
term results after thymoma resection: a series of 307 patients. J Thorac 
Cardiovasc Surg 1996;112:376–384.
 8. de Perrot M, Liu J, Bril V, McRae K, Bezjak A, Keshavjee SH. Prognostic 
significance of thymomas in patients with myasthenia gravis. Ann Thorac 
Surg 2002;74:1658–1662. 
 9. Gawrychowski J, Rokicki M, Gabriel A, Lackowska B, Czyzewski D. 
Thymoma–the usefulness of some prognostic factors for diagnosis and 
surgical treatment. Eur J Surg Oncol 2000;26:203–208.
 10. Detterbeck FC. Clinical value of the WHO classification system of thy-
moma. Ann Thorac Surg 2006;81:2328–2334.
 11. Ruffini E, Mancuso M, Oliaro A, et al. Recurrence of thymoma: anal-
ysis of clinicopathologic features, treatment, and outcome. J Thorac 
Cardiovasc Surg 1997;113:55–63.
 12. Akaogi E, Ohara K, Mitsui K, et al. Preoperative radiotherapy and sur-
gery for advanced thymoma with invasion to the great vessels. J Surg 
Oncol 1996;63:17–22.
 13. Singhal S, Shrager JB, Rosenthal DI, LiVolsi VA, Kaiser LR. Comparison 
of stages I-II thymoma treated by complete resection with or without 
adjuvant radiation. Ann Thorac Surg 2003;76:1635–41; discussion 1641. 
 14. Mangi AA, Wright CD, Allan JS, et al. Adjuvant radiation therapy for 
stage II thymoma. Ann Thorac Surg 2002;74:1033–1037.
 15. Nakahara K, Ohno K, Hashimoto J, et al. Thymoma: results with com-
plete resection and adjuvant postoperative irradiation in 141 consecutive 
patients. J Thorac Cardiovasc Surg 1988;95:1041–1047.
 16. Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymoma: 
results of 241 operated cases. Ann Thorac Surg 1991;51:152–156.
 17. Chen G, Marx A, Chen WH, et al. New WHO histologic classification 
predicts prognosis of thymic epithelial tumors: a clinicopathologic study 
of 200 thymoma cases from China. Cancer 2002;95:420–429.
 18. Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E, Harris 
NL. Thymoma. Histologic subclassification is an independent prognostic 
factor. Cancer 1994;74:606–617. 
 19. Rea F, Marulli G, Girardi R, et al. Long-term survival and prognos-
tic factors in thymic epithelial tumours. Eur J Cardiothorac Surg 
2004;26:412–418.
 20. Regnard JF, Zinzindohoue F, Magdeleinat P, Guibert L, Spaggiari L, 
Levasseur P. Results of re-resection for recurrent thymomas. Ann Thorac 
Surg 1997;64:1593–1598. 
 21. Kirschner PA. Reoperation for thymoma: report of 23 cases. Ann Thorac 
Surg 1990;49:550–4; discussion 555.
